OxRML/AgentSLR huggingface dataset:
Parameter: Human delay - Onset to ZIKV RNA clearance from saliva (Human delay)
Value: 14 Days (Median)
Exponent (base 10): 0
Uncertainty: 8 - 31 (IQR)
Statistical approach: Estimated model parameter
Population: Persons under investigation, sex: Both, ages 18 to 63
Country: Italy
Location: Padova and Pavia, travel-related
Setting: Hospital based, Unspecified
Sample size: 26
Study period: Jan 2016 - Jan 2017
Parameter: Human delay - Onset to ZIKV RNA clearance from semen (Human delay)
Value: 25 Days (Median)
Exponent (base 10): 0
Uncertainty: 14 - 29 (IQR)
Statistical approach: Estimated model parameter
Population: Persons under investigation, sex: Male, ages 18 to 63
Country: Italy
Location: Padova and Pavia, travel-related
Setting: Hospital based, Unspecified
Sample size: 10
Study period: Jan 2016 - Jan 2017
Parameter: Human delay - Onset to ZIKV IgM detection (Human delay)
Value: 8 Days (Median)
Exponent (base 10): 0
Uncertainty: 5 - 15 (IQR)
Statistical approach: Estimated model parameter
Population: Persons under investigation, sex: Both, ages 18 to 63
Country: Italy
Location: Padova and Pavia, travel-related
Setting: Hospital based, Unspecified
Sample size: 30
Study period: Jan 2016 - Jan 2017
Parameter: Human delay - Onset to ZIKV IgG detection (Human delay)
Value: 17 Days (Median)
Exponent (base 10): 0
Uncertainty: 12 - 26 (IQR)
Statistical approach: Estimated model parameter
Population: Persons under investigation, sex: Both, ages 18 to 63
Country: Italy
Location: Padova and Pavia, travel-related
Setting: Hospital based, Unspecified
Sample size: 30
Study period: Jan 2016 - Jan 2017
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 37 Percentage (%) (Central)
Exponent (base 10): 0
Uncertainty: 26 - 47 (95% CI)
Numerator/denominator: 18 / 49 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: General population, sex: Unspecified, ages 13 to 77
Country: France
Location: Society Islands, French Polynesia
Setting: Population based, Unspecified
Sample size: 49
Study period: Feb 2014 - Mar 2014
Parameter: Severity - proportion of symptomatic cases (Severity)
Value: 44 Percentage (%) (Central)
Exponent (base 10): 0
Uncertainty: 26 - 69 (95% CI)
Case definition: Other
Numerator/denominator: 8 / 18 (method: Naive)
Statistical approach: Observed sample statistic
Population: General population, sex: Unspecified, ages 13 to 77
Country: France
Location: Society Islands, French Polynesia
Setting: Population based, Unspecified
Sample size: 18
Study period: Feb 2014 - Mar 2014
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 45 Percentage (%) (Central)
Exponent (base 10): 0
Uncertainty: 38 - 52 (95% CI)
Numerator/denominator: 22 / 49 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: General population, sex: Unspecified, ages 7 to 86
Country: France
Location: Tuamotu Islands, French Polynesia
Setting: Population based, Unspecified
Sample size: 49
Study period: Feb 2014 - Mar 2014
Parameter: Severity - proportion of symptomatic cases (Severity)
Value: 55 Percentage (%) (Central)
Exponent (base 10): 0
Uncertainty: 34 - 75 (95% CI)
Case definition: Other
Numerator/denominator: 12 / 22 (method: Naive)
Statistical approach: Observed sample statistic
Population: General population, sex: Unspecified, ages 7 to 86
Country: France
Location: Tuamotu Islands, French Polynesia
Setting: Population based, Unspecified
Sample size: 22
Study period: Feb 2014 - Mar 2014
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 57 Percentage (%) (Central)
Exponent (base 10): 0
Uncertainty: 47 - 68 (95% CI)
Numerator/denominator: 28 / 49 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: General population, sex: Unspecified, ages 10 to 82
Country: France
Location: Marquesas Islands, French Polynesia
Setting: Population based, Unspecified
Sample size: 49
Study period: Feb 2014 - Mar 2014
Parameter: Severity - proportion of symptomatic cases (Severity)
Value: 57 Percentage (%) (Central)
Exponent (base 10): 0
Uncertainty: 39 - 75 (95% CI)
Case definition: Other
Numerator/denominator: 16 / 28 (method: Naive)
Statistical approach: Observed sample statistic
Population: General population, sex: Unspecified, ages 10 to 82
Country: France
Location: Marquesas Islands, French Polynesia
Setting: Population based, Unspecified
Sample size: 28
Study period: Feb 2014 - Mar 2014
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 59 Percentage (%) (Central)
Exponent (base 10): 0
Uncertainty: 39 - 80 (95% CI)
Numerator/denominator: 29 / 49 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: General population, sex: Unspecified, ages 7 to 84
Country: France
Location: Austral–Gambier Islands, French Polynesia
Setting: Population based, Unspecified
Sample size: 49
Study period: Feb 2014 - Mar 2014
Parameter: Severity - proportion of symptomatic cases (Severity)
Value: 66 Percentage (%) (Central)
Exponent (base 10): 0
Uncertainty: 48 - 83 (95% CI)
Case definition: Other
Numerator/denominator: 19 / 29 (method: Naive)
Statistical approach: Observed sample statistic
Population: General population, sex: Unspecified, ages 7 to 84
Country: France
Location: Austral–Gambier Islands, French Polynesia
Setting: Population based, Unspecified
Sample size: 29
Study period: Feb 2014 - Mar 2014
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 66 Percentage (%) (Central)
Exponent (base 10): 0
Uncertainty: 60 - 71 (95% CI)
Numerator/denominator: 312 / 476 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Children, sex: Both, ages 6 to 16
Country: France
Location: Society Islands, French Polynesia
Setting: School based, Unspecified
Sample size: 476
Study period: May 2014 - Jun 2014
Parameter: Severity - proportion of symptomatic cases (Severity)
Value: 71 Percentage (%) (Central)
Exponent (base 10): 0
Uncertainty: 66 - 76 (95% CI)
Case definition: Other
Numerator/denominator: 221 / 312 (method: Naive)
Statistical approach: Observed sample statistic
Population: Children, sex: Both, ages 6 to 16
Country: France
Location: Society Islands, French Polynesia
Setting: School based, Unspecified
Sample size: 312
Study period: May 2014 - Jun 2014
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 22 Percentage (%) (Central)
Exponent (base 10): 0
Uncertainty: 16 - 28 (95% CI)
Numerator/denominator: 154 / 700 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: General population, sex: Both, ages 4 to 88
Country: France
Location: Society Islands, French Polynesia
Setting: Population based, Unspecified
Sample size: 700
Study period: Sep 2015 - Nov 2015
Parameter: Severity - proportion of symptomatic cases (Severity)
Value: 47 Percentage (%) (Central)
Exponent (base 10): 0
Uncertainty: 40 - 55 (95% CI)
Case definition: Other
Numerator/denominator: 73 / 154 (method: Naive)
Statistical approach: Observed sample statistic
Population: General population, sex: Both, ages 4 to 88
Country: France
Location: Society Islands, French Polynesia
Setting: Population based, Unspecified
Sample size: 154
Study period: Sep 2015 - Nov 2015
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 0.8 Percentage (%) (Central)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 5 / 593 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Disaggregated by: Level of exposure
Population: Mixed groups, sex: Both, ages 18 to 75
Country: France
Location: French Polynesia
Setting: Population based, Unspecified
Sample size: 593
Study period: Jul 2011 - Oct 2013
Parameter: Human delay - Admission to care to Discharge from care (Human delay)
Value: 23 Days (Median)
Exponent (base 10): 0
Uncertainty: 9.5 - 36 (IQR)
Statistical approach: Observed sample statistic
Population: Persons under investigation, sex: Both, ages  to 
Country: Colombia
Location: Cucuta
Setting: Hospital based, Unspecified
Sample size: 6117
Study period: 29 Jun 2015 - 30 Jul 2016
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 100 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 29 / 29 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Other, sex: Both, ages  to 
Country: Colombia
Location: Cucuta
Setting: Hospital based, Unspecified
Sample size: 29
Study period: 29 Jun 2015 - 30 Jul 2016
Parameter: Reproduction number (Basic R0) (Reproduction number)
Value:  No units (Central)
Exponent (base 10): 0
Bounds: 2.68 - 4.57
Statistical approach: Estimated model parameter
Disaggregated by: Method
Reproduction number method: Growth rate Unspecified
Population: Persons under investigation, sex: Both, ages  to 
Country: Colombia
Location: Cucuta
Setting: Hospital based, Unspecified
Sample size: 6117
Study period: 29 Jun 2015 - 30 Jul 2016
Parameter: Attack rate (Attack rate)
Value: 1306 Per 100,000 population (Central)
Exponent (base 10): 0
Statistical approach: Unspecified
Disaggregated by: Age
Population: Persons under investigation, sex: Female, ages  to 
Country: Colombia
Location: Cucuta
Setting: Hospital based, Unspecified
Study period: 29 Jun 2015 - 30 Jul 2016
Parameter: Attack rate (Attack rate)
Value: 552 Per 100,000 population (Central)
Exponent (base 10): 0
Statistical approach: Unspecified
Disaggregated by: Age
Population: Persons under investigation, sex: Male, ages  to 
Country: Colombia
Location: Cucuta
Setting: Hospital based, Unspecified
Study period: 29 Jun 2015 - 30 Jul 2016
Parameter: Human delay - Diagnosis/test result to Onset of neurologic symptoms (Human delay)
Value: 7 Days (Median)
Exponent (base 10): 0
Uncertainty: 2 - 14.5 (IQR)
Statistical approach: Observed sample statistic
Population: Other, sex: Both, ages  to 
Country: Colombia
Location: Cucuta
Setting: Hospital based, Unspecified
Sample size: 29
Study period: 29 Jun 2015 - 30 Jul 2016
Parameter: Mutations - evolutionary rate (Mutations)
Value: 1.55 Substitutions/site/year (Mean)
Exponent (base 10): -3
Uncertainty: 0.00205 - 0.00106 (HPDI 95%)
Statistical approach: Estimated model parameter
Genome site: Whole genome sequence
Country: Multi-country: Americas
Location: Americas
Sample size: 49
Study period: Dec 2014 - Oct 2016
Parameter: Seroprevalence - IgM (Seroprevalence)
Exponent (base 10): 0
Case definition: Unspecified
Numerator/denominator: 24 / 410 (method: Unspecified)
Seroprevalence adjustment: Unspecified
Trimester exposed: Unspecified
Population: Pregnant women, sex: Female, ages  to 
Country: Saudi Arabia
Location: Najran city
Setting: Hospital based, Unspecified
Sample size: 410
Study period: Nov 2016 - Jul 2017
Parameter: Seroprevalence - IgG (Seroprevalence)
Exponent (base 10): 0
Case definition: Unspecified
Numerator/denominator: 52 / 410 (method: Unspecified)
Seroprevalence adjustment: Unspecified
Trimester exposed: Unspecified
Population: Pregnant women, sex: Female, ages  to 
Country: Saudi Arabia
Location: Najran city
Setting: Hospital based, Unspecified
Sample size: 410
Study period: Nov 2016 - Jul 2017
Parameter: Seroprevalence - IgM (Seroprevalence)
Exponent (base 10): 0
Case definition: Unspecified
Numerator/denominator: 0 / 52 (method: Unspecified)
Seroprevalence adjustment: Unspecified
Trimester exposed: Unspecified
Population: Other, sex: Unspecified, ages  to 
Country: Saudi Arabia
Location: Najran city
Setting: Hospital based, Unspecified
Sample size: 52
Study period: Nov 2016 - Jul 2017
Parameter: Seroprevalence - IgG (Seroprevalence)
Exponent (base 10): 0
Case definition: Unspecified
Numerator/denominator: 0 / 52 (method: Unspecified)
Seroprevalence adjustment: Unspecified
Trimester exposed: Unspecified
Population: Other, sex: Unspecified, ages  to 
Country: Saudi Arabia
Location: Najran city
Setting: Hospital based, Unspecified
Sample size: 52
Study period: Nov 2016 - Jul 2017
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 7 Percentage (%) (Central)
Exponent (base 10): 0
Case definition: Probable
Numerator/denominator: 36 / 547 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: Pregnant women, sex: Female, ages  to 
Country: United States
Location: Dallas, Texas
Setting: Travel based, Unspecified
Sample size: 547
Study period: 14 Mar 2016 - 1 Oct 2016
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 5.3 Percentage (%) (Central)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 29 / 36 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: Pregnant women, sex: Female, ages  to 
Country: United States
Location: Dallas, Texas
Setting: Travel based, Unspecified
Sample size: 547
Study period: 14 Mar 2016 - 1 Oct 2016
Parameter: Seroprevalence - HAI/HI (Seroprevalence)
Value: 56 Percentage (%) (Other)
Exponent (base 10): 0
Numerator/denominator: 150 / 267 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Disaggregated by: Age
Country: Nigeria
Location: Kainji Lake
Study period: 1980
Parameter: Reproduction number (Basic R0) - Sexual (Reproduction number)
Value:  No units ()
Exponent (base 10): 0
Bounds: 1.15 - 2.75
Statistical approach: Estimated model parameter
Disaggregated by: Other
Reproduction number method: Ross-Macdonald formula Vector-human
Country: Brazil
Location: Manacapuru
Study period: Feb 2014 - Feb 2015
Parameter: Human delay - serial interval (Human delay)
Value: 7.4 Days (Mean)
Exponent (base 10): 0
Uncertainty: 4.59 - 10.2 (95% CI)
Statistical approach: Estimated model parameter
Population: Persons under investigation, sex: Both, ages 4 to 49
Country: Singapore
Setting: Community based, 
Sample size: 10
Study period: Unspecified
Parameter: Reproduction number (Basic R0) (Reproduction number)
Value: 3.62 No units (Central)
Exponent (base 10): 0
Uncertainty: 3.48 - 3.77 (95% CI)
Statistical approach: Estimated model parameter
Disaggregated by: Time
Reproduction number method: Other Human-human
Population: Persons under investigation, sex: , ages  to 
Country: Singapore
Study period: 31 Jul 2016 - 1 Sep 2016
Parameter: Reproduction number (Effective, Re) (Reproduction number)
Value: 1.22 No units (Central)
Exponent (base 10): 0
Uncertainty: 1.19 - 1.24 (95% CI)
Statistical approach: Estimated model parameter
Disaggregated by: Time
Reproduction number method: Other 
Population: Persons under investigation, sex: , ages  to 
Country: Singapore
Study period: 1 Sep 2016 - 24 Nov 2016
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 0.3 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 3 / 1001 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Blood donors, sex: Both, ages 18 to 65
Country: Austria
Location: Tyrol
Setting: Population based, Unspecified
Sample size: 1001
Study period: Aug 2016 - Nov 2016
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 0.1 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 1 / 1001 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Blood donors, sex: Both, ages 18 to 65
Country: Austria
Location: Tyrol
Setting: Population based, Unspecified
Sample size: 1001
Study period: Aug 2016 - Nov 2016
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 0 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 0 / 4 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Blood donors, sex: Both, ages 18 to 65
Country: Austria
Location: Tyrol
Setting: Population based, Unspecified
Sample size: 1001
Study period: Aug 2016 - Nov 2016
Parameter: Mosquito delay - extrinsic incubation period (EIP10) (Mosquito)
Value:  E10 (Central)
Exponent (base 10): 0
Bounds: 9.7 - 25.6
Statistical approach: Estimated model parameter
Disaggregated by: Other
Population: Other, sex: , ages  to 
Country: Unspecified
Setting: Other, 
Study period: Unspecified
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 13 Percentage (%) ()
Exponent (base 10): 0
Numerator/denominator: 16 / 141 (method: )
Statistical approach: Observed sample statistic
Population: Children, sex: Both, ages  to 
Country: United States
Setting: Hospital based, 
Sample size: 141
Study period: 2016 - 2017
Parameter: Reproduction number (Basic R0) (Reproduction number)
Value: 0.4942 No units (Central)
Exponent (base 10): 0
Statistical approach: Estimated model parameter
Reproduction number method: Unspecified Unspecified
Population: Unspecified, sex: Unspecified, ages  to 
Country: Colombia
Setting: Unspecified, 
Study period: 2015
Parameter: Reproduction number (Effective, Re) (Reproduction number)
Value:  No units (Unspecified)
Exponent (base 10): 0
Bounds: 0.8822 - 0.941
Statistical approach: Estimated model parameter
Disaggregated by: Method
Reproduction number method: Compartmental model Other
Population: Persons under investigation, sex: Unspecified, ages  to 
Country: Brazil
Setting: Population based, 
Study period: 25 Mar 2016 - 14 Apr 2018
Parameter: Reproduction number (Effective; Re) - Vector-borne (Reproduction number)
Value: 0.8568 No units (Unspecified)
Exponent (base 10): 0
Statistical approach: Estimated model parameter
Reproduction number method: Compartmental model Vector-human
Population: Persons under investigation, sex: Unspecified, ages  to 
Country: Brazil
Setting: Population based, 
Study period: 25 Mar 2016 - 14 Apr 2018
Parameter: Reproduction number (Effective; Re) - Sexual (Reproduction number)
Value: 0.05 No units (Unspecified)
Exponent (base 10): 0
Statistical approach: Estimated model parameter
Reproduction number method: Compartmental model Human-human
Population: Persons under investigation, sex: Unspecified, ages  to 
Country: Brazil
Setting: Population based, 
Study period: 25 Mar 2016 - 14 Apr 2018
Parameter: Reproduction number (Basic R0) (Reproduction number)
Value: 1.8162 No units (Unspecified)
Exponent (base 10): 0
Statistical approach: Estimated model parameter
Reproduction number method: Compartmental model Other
Population: Persons under investigation, sex: Unspecified, ages  to 
Country: Brazil
Setting: Population based, 
Study period: 25 Mar 2016 - 14 Apr 2018
Parameter: Reproduction number (Basic R0) - Vector-borne (Reproduction number)
Value: 1.7133 No units (Unspecified)
Exponent (base 10): 0
Statistical approach: Estimated model parameter
Reproduction number method: Compartmental model Vector-human
Population: Persons under investigation, sex: Unspecified, ages  to 
Country: Brazil
Setting: Population based, 
Study period: 25 Mar 2016 - 14 Apr 2018
Parameter: Reproduction number (Basic R0) - Sexual (Reproduction number)
Value: 0.1999 No units (Unspecified)
Exponent (base 10): 0
Statistical approach: Estimated model parameter
Reproduction number method: Compartmental model Human-human
Population: Persons under investigation, sex: Unspecified, ages  to 
Country: Brazil
Setting: Population based, 
Study period: 25 Mar 2016 - 14 Apr 2018
Parameter: Reproduction number (Basic R0) - Sexual (Reproduction number)
Value: 0.8812 No units (Unspecified)
Exponent (base 10): 0
Statistical approach: Estimated model parameter
Reproduction number method: Compartmental model Vector-human
Population: General population, sex: Unspecified, ages  to 
Country: Colombia
Setting: Population based, Unspecified
Study period: 2016
Parameter: Reproduction number (Basic R0) - Sexual (Reproduction number)
Value: 1.66 No units (Central)
Exponent (base 10): 0
Statistical approach: Estimated model parameter
Reproduction number method: Next generation matrix Vector-human
Population: General population, sex: Unspecified, ages  to 
Country: Brazil
Location: Itabuna
Setting: Population based, Unspecified
Study period: 2016
Parameter: Reproduction number (Basic R0) - Sexual (Reproduction number)
Value: 1.8 No units (Central)
Exponent (base 10): 0
Statistical approach: Estimated model parameter
Reproduction number method: Next generation matrix Vector-human
Population: General population, sex: Unspecified, ages  to 
Country: Brazil
Location: Cuiaba
Setting: Population based, Unspecified
Study period: 2016
Parameter: Reproduction number (Basic R0) - Sexual (Reproduction number)
Value: 2.76 No units (Central)
Exponent (base 10): 0
Statistical approach: Estimated model parameter
Reproduction number method: Next generation matrix Vector-human
Population: General population, sex: Unspecified, ages  to 
Country: Brazil
Location: Goiania
Setting: Population based, Unspecified
Study period: 2016
Parameter: Reproduction number (Basic R0) - Sexual (Reproduction number)
Value: 1.87 No units (Central)
Exponent (base 10): 0
Statistical approach: Estimated model parameter
Reproduction number method: Next generation matrix Vector-human
Population: General population, sex: Unspecified, ages  to 
Country: Brazil
Location: Rio de Janeiro
Setting: Population based, Unspecified
Study period: 2016
Parameter: Reproduction number (Effective; Re) - Sexual (Reproduction number)
Value:  No units (Unspecified)
Exponent (base 10): 0
Bounds: 0.85 - 1.71
Statistical approach: Unspecified
Reproduction number method: Next generation matrix Vector-human
Population: Unspecified, sex: Unspecified, ages  to 
Country: Brazil
Location: "north-eastern"
Setting: Unspecified, Unspecified
Study period: Jan 2015 - Sep 2016
Parameter: Relative contribution - vector-borne (Relative contribution)
Value: 98.6 Percentage (%) (Median)
Exponent (base 10): 0
Statistical approach: Estimated model parameter
Population: Unspecified, sex: Unspecified, ages  to 
Country: Brazil
Location: "north-eastern"
Setting: Unspecified, Unspecified
Study period: Jan 2015 - Sep 2016
Parameter: Relative contribution - sexual (Relative contribution)
Value: 1.4 Percentage (%) (Median)
Exponent (base 10): 0
Statistical approach: Estimated model parameter
Population: Unspecified, sex: Unspecified, ages  to 
Country: Brazil
Location: "north-eastern"
Setting: Unspecified, Unspecified
Study period: Jan 2015 - Sep 2016
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 35 Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 26 - 48 (95% CI)
Bounds: 15 - 57
Case definition: Lab confirmed
Numerator/denominator:  / 5108 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Estimated model parameter
Disaggregated by: Region
Population: Other, sex: Unspecified, ages 2 to 59
Country: Brazil
Location: Belo Horizonte, Salvador, Laranjeiras, Fortaleza, Recife, Cuiaba and Campo Grande, Porto Velho
Setting: Other, 
Sample size: 5108
Study period: Jul 2016 - Jun 2019
Parameter: Reproduction number (Basic R0) (Reproduction number)
Value: 1.54 No units ()
Exponent (base 10): 0
Uncertainty: 1.35 - 1.92 (95% CI)
Bounds: 1.18 - 2.33
Statistical approach: Estimated model parameter
Disaggregated by: Region
Reproduction number method: Other Unspecified
Population: Other, sex: Unspecified, ages 2 to 59
Country: Brazil
Location: Belo Horizonte, Salvador, Laranjeiras, Fortaleza, Recife, Cuiaba and Campo Grande, Porto Velho
Setting: Other, 
Sample size: 5108
Study period: Jul 2016 - Jun 2019
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 22 Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 7 - 41 (95% CI)
Case definition: Lab confirmed
Numerator/denominator:  / 817 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Estimated model parameter
Population: Other, sex: Unspecified, ages 2 to 59
Country: Brazil
Location: Belo Horizonte
Setting: Other, 
Sample size: 817
Study period: Jul 2016 - Jun 2019
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 29 Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 11 - 52 (95% CI)
Case definition: Lab confirmed
Numerator/denominator:  / 494 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Estimated model parameter
Population: Other, sex: Unspecified, ages 2 to 59
Country: Brazil
Location: Salvador, Bahia
Setting: Other, 
Sample size: 494
Study period: Jul 2016 - Jun 2019